Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets: 2022-2025

Historic Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $300.0 million.

  • Taysha Gene Therapies' Current Assets rose 85.66% to $300.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.0 million, marking a year-over-year increase of 85.66%. This contributed to the annual value of $142.1 million for FY2024, which is 5.16% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Current Assets stood at $300.0 million for Q3 2025, which was down 5.16% from $316.3 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Current Assets peaked at $316.3 million during Q2 2025, and registered a low of $43.0 million during Q3 2022.
  • For the 3-year period, Taysha Gene Therapies' Current Assets averaged around $163.4 million, with its median value being $149.9 million (2023).
  • Over the last 5 years, Taysha Gene Therapies' Current Assets had its largest YoY gain of 299.53% in 2023, and its largest YoY loss of 32.31% in 2023.
  • Over the past 4 years, Taysha Gene Therapies' Current Assets (Quarterly) stood at $96.4 million in 2022, then soared by 55.44% to $149.9 million in 2023, then dropped by 5.16% to $142.1 million in 2024, then spiked by 85.66% to $300.0 million in 2025.
  • Its last three reported values are $300.0 million in Q3 2025, $316.3 million for Q2 2025, and $120.7 million during Q1 2025.